Navigation Links
St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial
Date:11/9/2009

St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.

Under the clinical protocol, St. Jude will refer patients to receive proton therapy at the UF Proton Therapy Institute in Jacksonville, Fla. The purpose of the clinical study is to improve response rates and decrease treatment-related side effects.

Proton therapy is being studied as a way to reduce potential damage to healthy tissue that may result from conventional radiation therapy. This is especially important in treating children with brain and spinal tumors to potentially avoid interference with development, growth and cognitive functioning.

St. Jude has the world's largest protocol-based, pediatric brain tumor research and treatment program, which puts it in an excellent position to scientifically document the advantages realized with proton beam radiation therapy.

"Proton beam therapy is potentially of great importance to St. Jude and our patients," said Dr. Joseph H. Laver, St. Jude executive vice president and clinical director. "Although most proton facilities operating in the U.S. recognize pediatrics as a major area of focus, there is very little meaningful data using this modality in children. Working with UF Proton Therapy Institute, we are well-positioned to answer key questions regarding this therapy for children with cancer."

St. Jude patients accepted for the clinical study will be in Jacksonville for proton therapy treatment for six to eight weeks. It is expected that up to 15 patients will receive treatment during the first year of the study. While in Jacksonville, hospital care for St. Jude patients will be provided by Nemours Children's Clinic Jacksonville and Wolfson Children's Hospital. The Ronald McDonald House in Jacksonville will house St. Jude patients while they are receiving treatment in Florida.

"It is central to our mission to realize the full potential of protons in the treatment of children," said Dr. Nancy Mendenhall, medical director at UF Proton Therapy Institute. "In cooperation with St. Jude, we will have both clinical and research expertise to provide the best outcomes for patients and to create new knowledge that will guide the development of proton therapy for future patients."

St. Jude leads the field in the application of intensified modulated radiation therapy, known as IMRT. The technique is effective at avoiding damage to adjacent tissues; however, IMRT can still deliver significant radiation doses to underlying tissues resulting in unavoidable side effects for some children. Proton therapy can be focused more precisely and intensely on specific areas of cancerous activity. Protons can also be energized for a desired degree of tumor penetration, thus sparing underlying tissues from radiation exposure.

UF Proton Therapy Institute is one of only six proton therapy centers in the United States. Since opening in August 2006, UF Proton Therapy Institute has treated 100 pediatric patients.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
2. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
3. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
4. Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance
5. Proton-powered pooping
6. Wyeth Announces Launch of Own Generic Version of PROTONIX
7. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
8. Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment
9. Gastric juice for diagnosis of H. pylori infection in patients on proton pump inhibitors
10. Varian Medical Systems to Develop Interface Between the ARIA(TM) Oncology Information System and the Monarch250(TM) Proton Radiotherapy System From Still River Systems
11. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: